Literature DB >> 2014965

Impact of dosage schedule on the efficacy of gentamicin, tobramycin, or amikacin in an experimental model of Serratia marcescens endocarditis: in vitro-in vivo correlation.

G Potel1, J Caillon, B Fantin, J Raza, F Le Gallou, J Y Lepage, P Le Conte, D Bugnon, D Baron, H Drugeon.   

Abstract

Aminoglycosides are usually considered to be concentration-dependent antibiotics and to have similar pharmacodynamic and pharmacokinetic properties. To verify the equivalent activity of the aminoglycosides on a susceptible strain, we tested the killing rate of three aminoglycosides (gentamicin, tobramycin, and amikacin) on one strain of Serratia marcescens both in vitro and in vivo by using a rabbit model of left-ventricle endocarditis. Despite, similar MICs, the time-kill curve of gentamicin was consistently better than those of amikacin and tobramycin, whatever the concentration of each antibiotic used (1, 2, 4, 8, 16, or 32 mg/liter), after a 5-h incubation. The in vivo bacterial reduction in the vegetations was measured 24 h after administration of an intravenous 48-mg/kg bolus of each antibiotic or at the end of a 24-h continuous intravenous infusion of the same dose. Gentamicin was significantly more effective when administered as a bolus than when administered as a continuous infusion (2.8 +/- 0.2 versus 6.4 +/- 1.5 log10 CFU/g of vegetation, respectively; P less than 0.01), whereas amikacin was more effective as a continuous infusion than as a bolus injection (3.6 +/- 2.0 versus 7.5 +/- 1.3 log10 CFU/g of vegetation, respectively; P less than 0.01). Tobramycin was not very effective, whatever the dosage tested (approximately 6.5 to 7 log10 CFU/g). These results suggest that concentration-dependent bactericidal activities, both in vitro and in vivo, may vary greatly among aminoglycosides despite similar MICs.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2014965      PMCID: PMC244950          DOI: 10.1128/AAC.35.1.111

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  Determination of optimal dosage regimen for amikacin in healthy volunteers by study of pharmacokinetics and bactericidal activity.

Authors:  R Garraffo; H B Drugeon; P Dellamonica; E Bernard; P Lapalus
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

2.  Dynamics of ceftazidime-pefloxacin interaction shown by a new killing curve-chequerboard method.

Authors:  H B Drugeon; J Caillon; M E Juvin; J L Pirault
Journal:  J Antimicrob Chemother       Date:  1987-02       Impact factor: 5.790

3.  Emergence of resistance to beta-lactams, aminoglycosides, and quinolones during combination therapy for infection due to Serratia marcescens.

Authors:  C C Sanders; C Watanakunakorn
Journal:  J Infect Dis       Date:  1986-03       Impact factor: 5.226

4.  [Comparison of the bactericidal activity of three aminosides: gentamicin, tobramycin and amikacin].

Authors:  M E Juvin; H B Drugeon; J Caillon; J L Pirault
Journal:  Pathol Biol (Paris)       Date:  1987-05

5.  Evidence for a chromosomal site specifying amikacin resistance in multiresistant Serratia marcescens.

Authors:  J F John; W F McNeill; K E Price; P A Kresel
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

6.  Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration.

Authors:  R D Moore; P S Lietman; C R Smith
Journal:  J Infect Dis       Date:  1987-01       Impact factor: 5.226

7.  Impact of dosing intervals on activity of gentamicin and ticarcillin against Pseudomonas aeruginosa in granulocytopenic mice.

Authors:  A U Gerber; W A Craig; H P Brugger; C Feller; A P Vastola; J Brandel
Journal:  J Infect Dis       Date:  1983-05       Impact factor: 5.226

8.  The acetylation of 6'-amino group of amikacin by a new enzyme prepared from serratia sp.

Authors:  T Morohoshi; M Toriya; S Yokoiyama; K Fujimoto; K Hayano; S Goto; A Tsuji
Journal:  J Antibiot (Tokyo)       Date:  1984-12       Impact factor: 2.649

9.  Comparative distribution of gentamicin, tobramycin, sisomicin, netilmicin, and amikacin in interstitial fluid in rabbits.

Authors:  C Carbon; A Contrepois; S Lamotte-Barrillon
Journal:  Antimicrob Agents Chemother       Date:  1978-03       Impact factor: 5.191

10.  Experimental endocarditis. II. Staphylococcal infection of the aortic valve following placement of a polyethylene catheter in the left side of the heart.

Authors:  B B Perlman; L R Freedman
Journal:  Yale J Biol Med       Date:  1971-10
View more
  8 in total

1.  Simulation of human gentamicin pharmacokinetics in an experimental Enterococcus faecalis endocarditis model.

Authors:  Laurent Dubé; Jocelyne Caillon; Christèle Gras-Le Guen; Cédric Jacqueline; Marie-France Kergueris; Jean-Claude Granry; Gilles Potel; Denis Bugnon
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

2.  A pharmacodynamic model for the action of the antibiotic imipenem on Pseudomonas aeruginosa populations in vitro.

Authors:  P H Berg; E O Voit; R L White
Journal:  Bull Math Biol       Date:  1996-09       Impact factor: 1.758

3.  Comparative in vitro pharmacodynamics of imipenem and meropenem against Pseudomonas aeruginosa.

Authors:  R White; L Friedrich; D Burgess; D Warkentin; J Bosso
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

4.  Single daily dosing of antibiotics: importance of in vitro killing rate, serum half-life, and protein binding.

Authors:  G Potel; N P Chau; B Pangon; B Fantin; J M Vallois; F Faurisson; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

5.  Identification of factors affecting in vivo aminoglycoside activity in an experimental model of gram-negative endocarditis.

Authors:  G Potel; J Caillon; F Le Gallou; D Bugnon; P Le Conte; J Raza; J Y Lepage; D Baron; H Drugeon
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

Review 6.  What is the evidence for once-daily aminoglycoside therapy?

Authors:  M L Barclay; E J Begg; K G Hickling
Journal:  Clin Pharmacokinet       Date:  1994-07       Impact factor: 6.447

Review 7.  Parenteral aminoglycoside therapy. Selection, administration and monitoring.

Authors:  C R Kumana; K Y Yuen
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546

8.  Fusogenic porous silicon nanoparticles as a broad-spectrum immunotherapy against bacterial infections.

Authors:  Byungji Kim; Qinglin Yang; Leslie W Chan; Sangeeta N Bhatia; Erkki Ruoslahti; Michael J Sailor
Journal:  Nanoscale Horiz       Date:  2021-02-18       Impact factor: 10.989

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.